15 Sep
Podcasts

MAP Podcast #002: Prof. Dr. Wagschal – What can we expect from the upcoming elections?

In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.

They are discussing latest forecasts and potential policy implications.

Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.

Another important part is in the potential (new) coalitions and their likely impact on the health care market.

Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:

marketaccess-pricingstrategy.de

 

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

31 Aug
Podcasts

MAP Podcast #001: Dr. Matthias Flume – AMNOG will change in 2022, but how?

In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.

Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?

 

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

27 Aug
Latest News

There is more than Mozart, Sissi and Sacher cake! The pragmatic reimbursement pathways in Austria?!

Austria is in the center of Europe and has a high quality health care system. Recently there have been major changes within the insurance system which might also have longer term impact on reimbursement. Currently reimbursement pathways are seen as more pragmatic in comparison to other countries – not only in the inpatient setting. Listen and learn from the Austrian experts Dr. Stefan Walzer and Dr. Thorsten Peske.

Register now!

25 Aug
Latest News

Price negotiations in Germany – live and let die or die hard?!

Price negotiations for drugs follow clear and strict frames and rules in Germany. Anyhow, there is flexibility in terms of negotiations and price anchors including the tactical move into an arbitration board decision. Even more important is the related contract between the head association of statutory health insurance fund and the respective pharma company. The experienced negotiator Dr. Stefan Walzer and Bibiane Schulte-Bosse will discuss whether the process is a „live and let die“ or „die hard“ – from the different perspectives.

Register now!

25 Jun
Latest News

German elections ahead – potential outcomes and implications on health care market access

On September 26 2021 there will be the next national elections in Germany. Current forecasts predict a change in the political environment which might also change the current health care politics. Currently various debates are on-going with respect to the health care market including a change in the insurance system, update on the AMNOG process, further digitalization and much more.
Prof. Uwe Wagschal, well-known political scientist will present latest forecasts and potential implications from a political side, whereas Dr. Stefan Walzer will come up with various scenarios with respect to the impact on the health care market access.

Register now!

08 Jun
Latest News

1 year DiGAs in Germany – Garden of Eden?

One year ago, a special reimbursement process for digital health applications (so-called DiGAs) was implemented in Germany. Until June 2021, 15 DiGAs have been approved by the authority BfArM and the first one is starting price negotiations now.
DiGA experts Dr. Stefan Walzer and Ariane Schenk (Bitkom Health) will discuss the following items:

Process for DiGAs in Germany
Success factors for DiGAS
Price negotiation frame for DiGAs
Outlook into the future, e.g. DiPAs

Register now for free!

03 May
Latest News

The end in drug price negotiations in Germany? The “mystic” arbitration board?!

Within the German pharmaceutical market access process a core component is the price negotiation which follows in the second part of the evaluation. Negotiations will be conducted between pharmaceutical company and the Head Association of the Statutory Health Insurance Funds. In case no agreement is reached, each party could call the arbitration board which could then come up with a price agreement. The presenters will discuss the decisions of the last 10 years and potential implications. Furthermore, Prof. Wasem as the former head of the arbitration board will discuss the view of it and his experience.

Register now!

06 Apr
Latest News

Access to German hospitals – pathways to follow

The pathway to German hospitals for medical devices, digital health applications and drugs can be straight forward in Germany. However, in the meantime there are various pathways available including the famous “NUB” and the newly introduced Hospital Future Act as well as experimental coverage and innovation fund applications. Additionally, investment goods need to differentiate between hospital ownerships.
The presenters, both long-lasting members of the Inpatient committee at the German Health Economic Association, will discuss the various pathways and applicability as well as the correlation to the annual budget negotiations of hospitals and will show the various aspects to consider when planning a launch into the German hospital setting.

Register now!

26 Mar
Latest News

MArS goes Clubhouse (again) – 10 years AMNOG

After a great webinar on “10 years AMNOG” on Thursday evening, we are happy to announce that the discussions are expanded into the German-speaking community! MArS Market Access & Pricing Strategy GmbH goes (again) to Clubhouse!! The session on April 1 2021 will be recorded and made available afterwards as well – but even better, join us and discuss directly with well-known experts: Dr. Stefan Walzer, Prof. Dr. David Matusiewicz, Bibiane Schulte-Bosse, Dr. Mathias Flume, Heiko Schellhorn, Prof. Dr. Thomas Hammerschmidt – moderation as always by Lutz Vollmer!!

Join us at Clubhouse!!

08 Mar
Latest News

10 years AMNOG – what have we learnt for drug development and pricing?

10 years ago, the German reimbursement system for drugs changed significantly. The AMNOG including a benefit assessment and price negotiation was launched. Threats were seen, but also opportunities – the AMNOG frame was criticized and in some aspects also changed over time. A learning system – as some say.
The speakers have worked and shaped the AMNOG process also before its implementation and have also been working since the start of it in various roles and on different products. The presentation and discussions will shows the following key aspects:

  • What are key success factors for a optimal AMNOG process?
  • Are there any guidances for clinical development?
  • How is the benefit rating and price negotiation correlated? What are drivers?
  • What can we expect in the future from the AMNOG?

Register now!